As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

The cutting-edge technology used in COVID-19 shots may lead to new treatments for other diseases. But some conservatives are ...

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Moderna (NasdaqGS:MRNA) saw an 11% increase in share price over the last week, likely influenced by recent legal and financial developments. The announcement of multiple international lawsuits from ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Vaccine manufacturers would have to waive indemnity from ... COVID-19 vaccines made by Pfizer and Moderna are both mRNA ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

On March 4, 2025, filings revealed that CEO Stephane Bancel purchased 160,314 shares of MRNA stock between $31.04 and $31.53, ...